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This study investigated the use of DNA ampliﬁcation ﬁngerprinting (DAF) to identify biomarkers useful in the elucidating genetic
factorsthatleadtocarcinogenesis.TheDNAampliﬁcationﬁngerprinting(DAF)techniquewasusedtogenerateﬁngerprintproﬁles
of a normal human mammary epithelial cell line (MCF-10A) and a human breast cancer cell line (MCF-7). When compared with
one another, a polymorphic biomarker gene (262 base pairs (bps)) was identiﬁed in MCF-10A but was not present in MCF-7. This
gene was cloned from the genomic DNA of the MCF-10A cell line, and subjected to Genbank database analysis. The analysis of
the nucleotide sequence polymorphic marker (Genbank account: AC079630) shows that this biomarker has 100% homology with
the nucleotide sequence of human chromosome 12 BAC RP11-476D10 (bps 19612-19353). The nucleotide sequence was used for
possible protein translation product and the result obtained indicated that the gene codes for hypothetical protein XF2620. In
order to evaluate the eﬀects that the 262bps biomarker would have on the morphology of MCF-7 cells, it was transfected into
MCF-7 cells. There were observable changes in the morphology of the transfected cells. These changes included an increase in cell
elongation and a decrease in cell aggregation.
Copyright © 2006 Brian H. Crawford et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
DNA “ﬁngerprinting” has been used for genome linkage, ge-
netic variation, population and pedigree analysis, forensic
identiﬁcation, localization of disease loci, and epidemiology
[1–3]. Variation in the nucleotide sequence of DNA has been
exploited to produce characteristic ﬁngerprinting because of
its plasticity, ubiquity, and stability [4–6].
Cancer cells typically possess hundreds and even thou-
sands of genomic errors, and unique patterns of genetic mu-
tations are found in virtually every diﬀerent tumor [7, 8].
Unlike classical genetic diseases, there are no well-deﬁned
correspondences between the genetic mutations present in
cancer populations and the cellular characteristics of the ma-
lignant phenotype [9].
The most common form of cancer among women is
breast cancer [10]. Although it is the second leading cause
of mortality among females, the pathogenesis of the dis-
ease remains unclear [11, 12]. Most mutations in hu-
man malignancies were identiﬁed by conventional meth-
ods such as single-strand conformational polymorphism
(SSCP) and DNA sequencing [13]. Other methods, such as
denaturing gradient gel electrophoresis, heteroduplex analy-
sis, and cleavage methods [14] have also been used. All these
methods are relatively time-consuming, labor intensive, and
sequential processes.
The ampliﬁcation fragment length polymorphism AFLP
involves the enzymatic ampliﬁcation of template DNA di-
rected by one or more arbitrary oligonucleotide primers to
produce a characteristic spectrum of products, a part of
whichcouldbepolymorphic.Theprocedureisfast,indepen-
dent of prior genetic and biochemical knowledge of the or-
ganismtested,andallowstailoringofthenumberofproducts
and polymorphisms generated [15]. DNA ampliﬁcation ﬁn-
gerprinting (DAF) is one of the best technological develop-
mentsduetoitsuseofthesimplestandmostrelaxedampliﬁ-
cationconditions andtheshortestprimers,andoﬀeringhigh
resolution. DAF is basedonthe principle thatDNA fromtwo
diﬀerent sources has diﬀerent distributions of speciﬁc DNA
sites. The DNA at these sites can be cut with restriction nu-
cleases producing a unique set of DNA fragments from the
entire genome of the organism. The DAF technique can be
accomplished by sorting these fragments by size using SDS-
polyacrylamide gel electrophoresis [4].2 Journal of Biomedicine and Biotechnology
Breast cancer and other malignancies result from step-
wise genetic alternations of normal host cells. Genome in-
stability promotes great potential to develop genetic changes
such as gene loss, gene ampliﬁcation, point mutation, and
chromosomal translocations [16]. In regards to breast can-
cer, loss of heterozygosity (gene loss) and changes in gene
copy number cause the development and progression of the
disease [17, 18].
In the present investigation, we used the DAF technique
intheidentiﬁcationofapolymorphicgenepresentinnormal
human mammary epithelial cell line, MCF-10, but absent in
human breast cancer cell line, MCF-7.
MATERIALS AND METHODS
Celllines
Normal human breast epithelial cells (MCF-10A) and hu-
man breast cancer cells (MCF-7) used for this study were ob-
tained from the ATCC (Manassas, Va) company.
IsolationofgenomicDNAandgenerationof
ﬁngerprintingproﬁle
DNAzol genomic DNA isolation reagent (Molecular Re-
search Center, Inc, Cincinnati, Ohio) was used to isolate the
genomicDNAofhumanmammaryepithelialcellline(MCF-
10A) and breast cancer cell line (MCF-7). DNA ampliﬁca-
tion was performed by using a solution (25µL) containing
2ngoftemplateDNA,0.3units/µL of Amplitaq DNA poly-
merase (Stoﬀel fragment) from Thermus aquaticus (Perkin-
Elmer/cetus, Norwalk, Conn, USA), 200µMo fe a c hd e -
oxynucleotide triphosphate (Pharmacia LKB Biotechnology
Inc, Piscataway, NJ, USA), 6mM MgCl2, 10mM Tris-HCl
(pH8.3),and10mMKCl.Thesolutionalsocontained0.3µL
of DAF arbitrary primer (8–10 nucleotides in length) that
required low stringency cycles to amplify DNA polymor-
phism [19]. Due to the fact that there was no known evi-
dence of which primers would yield polymorphic products,
10 DAF primers from each of the 4 series (A, B, C, and D;
totaling forty primers) were randomly selected and used for
both MCF-10A and MCF-7 cell lines. Out of these 40 DAF
primers, only one (A25 (GCCCGTGC)) yielded polymor-
phic markers in three separate experiments, giving evidence
of reproducible results. The remaining 39 DAF primers did
not yield any polymorphisms. The solution was overloaded
with two drops of mineral oil and the samples were ampli-
ﬁed in an Ericomp thermocycler (Ericomp Inc, San Diego,
Calif, USA) for 35 two-step cycles of 1 second at 96◦Ca n d1
second at 30◦C. The heating and cooling rates of the thermo-
cycler were 23◦C/min and 14◦C/min, respectively. 3µL of the
ampliﬁcation reaction was loaded with 3µL of loading buﬀer
(5M urea, 3% ﬁcoll, 0.12% Tris, 1.12% EDTA, 0.02% xylene
cyanol, and 0.02% bromophenol blue). Polyacrylamide gel
electrophoresis [4, 15] was used to separate DNA ampliﬁca-
tion fragments. Electrophoresis was run at 100V, until the
dye front was approximately 1cm from the end of the gel.
A silver staining procedure [15] that detects 1pg DNA/mm2
band cross-section was used to observe DNA. The gels were
permanently preserved using polyester-backed gels by soak-
ing in 50% ethanol for 10 minutes and drying at room tem-
perature.
Isolationandcloningofbiomarkersequence
The polymorphic band was excised from the wet polyacry-
lamide gel and submerged in 20µLo fT Eb u ﬀer (10mM
Tris, 1mM EDTA). The mixture was heated for 20 min-
utes at 90◦C and stored at 4◦C for 2 days. TwoµL of the
mixture was used for the DAF PCR reaction with DAF ar-
bitrary primer, A25. ThreeµL of the PCR product was lig-
ated into pCR II and transformed into one-shot compe-
tent cells (according to the procedure of TA cloning kit dual
promoter (pCR II), Invitrogen Life Technology, Carlsbad,
California, USA—version H). A white color on LB plates
(1.0% tryptone, 50µg/mL ampicillin, 0.5% becto-yeast ex-
tract, 1.0% NaCl, and 0.15% agar) identiﬁed the colonies
that contained the fragment, which was generated using X-
gal due to the expression of the lac promoter of the pCR II
vector. Individual white colonies of the polymorphic band
were digested by EcoRI restriction enzyme and run on a 1%
agarose gel stained with ethidium bromide (0.5µg/mL). The
gelwasviewedunderUVlighttoidentifythebandsthatcon-
tainedthefragment.TheexpectedcoloniesweregrowninLB
medium (1% tryptone, 0.5% yeast extract, 1% NaCl, ampi-
cillin antibiotic (50µg/mL) (pH 7.0)) over night at 37◦Co n
electrical shaker at 225rpm. The plasmid DNA was puri-
ﬁed by the Wizard Plus Miniprep DNA puriﬁcation system
(Promega Corporation, Madison, Wisconsin, USA). The pu-
riﬁed plasmid DNA was sequenced by DNA sequencer (ABI
Prism, Model 3100, Version 3.7) at Morehouse School of
Medicine in Atlanta, Georgia, USA.
TRANSFECTION OF MCF-7 CELLS
Two µg of the isolated 262bps DNA fragment were added
to 100µL of OPTI-MEM medium. This mixture was com-
bined with 10µL of CELLFECTIN reagent in 100µL OPTI-
MEM medium. The combined mixture was gently mixed
and incubated at room temperature for 30 minutes. The
incubated mixture was carefully overlaid over the MCF-7
c e l l s( 2t o3× 105 cells in 4mL of growth medium supple-
mented with serum) and incubated for 24 hours in a CO2
incubator [20]. The transfection mixtures were washed with
2mL of serum-free growth medium without antibacterial
agents. Then 1.8mL serum-free growth medium was added
to each tube containing CELLFECTIN reagent-DNA com-
plexes, mixed gently, and overlaid onto the cells. The cells
were incubated for 24 hours at 37◦Ci naC O 2 incubator. The
DNA-containing medium was replaced with 4mL of growth
medium(supplementedwithserum)andthecellswereincu-
bated at 37◦Ci naC O 2 incubator for another 48 hours. The
cells were trypsinized and the genomic DNA of the trans-
fected MCF-7, untransfected MCF-7 (control), and MCF-
10A (control) cells were isolated using DNAzol genomic








DAF PCR ampliﬁcation reaction mixture was loaded with 3µL of loading buﬀer. Electrophoresis was continued at 100V until the dye front
was approximately 1cm from the end of the gel. The ampliﬁcation fragments were separated by polyacrylamide gel (5%) electrophoresis.
DNA was visualized using a fast and sensitive silver staining procedure that detects 1pg DNA/mm band cross-section. The polymorphic





Samples containing expected polymorphic marker
262bps
Figure 2: Restriction mapping of the plasmid containing the expected polymorphic marker. The DNA of 30 individual colonies having the
expected polymorphic marker was extracted by the DNAzol extraction method. The DNA (4µL), restriction enzyme (EcoRI, 20U/mL)
(1µL), buﬀer (10X)(2µL), and water (13µL) were mixed together. The reaction mixture was incubated at a 37◦C for 2 hours in a water bath.
15µL of reaction mixture with 1µL of loading buﬀer was loaded into a 1.0% agarose gel, stained with ethidium bromide (0.5µg/mL), and
viewed under UV light. These results were reproduced in three supplementary experiments.




The DNA ampliﬁcation ﬁngerprinting (DAF) technique was
used to generate ﬁngerprint proﬁles of a normal human
mammaryepithelialcellline(MCF-10A)andahumanbreast
cancer cell line (MCF-7). When compared with one an-
other, a polymorphic biomarker gene (262bps) and others
were identiﬁed in MCF-10A but were not present in MCF-
7( Figure 1). Although there were other biomarker genes
present, this study focuses only on the 262bps biomarker.
The other biomarkers will be subjected to further studies.
The 262bps biomarker was isolated and excised from
the wet SDS-PAGE gel and ligated into the pCR II vector
to obtain a suﬃcient quantity of DNA for sequencing. We
conﬁrmed the expected biomarker by EcoRI digestion of the
ligatedvectorpCRII(Figure 2).Outofthe30whitecolonies,
only 8 possessed the expected polymorphic biomarker, as
determined by its relative movement when compared to the










The biomarker sequence was analyzed by Genbank
database account and revealed that the gene was signiﬁcantly4 Journal of Biomedicine and Biotechnology
(a) MCF-7 (control) (b) MCF-10A (c) Transfected MCF-7 cells
Figure 3: Cell morphology of MCF-7 cells transfected with the 262bps polymorphic biomarker gene. MCF-7 cells were transfected with the
262bps polymorphic marker gene using CELLFECTIN reagent-DNA complexes. The cells were incubated for 24 hours at 37◦Ci naC O 2 in-
cubator. The DNA-containing medium was replaced with 4mL of growth medium (supplemented with serum) and the cells were incubated
(37◦C) in a CO2 incubator for 48 hours. The cells were trypsinized, and the genomic DNA was isolated by DNAzol genomic DNA isolation
reagent. Visualization of the cells was performed using Axiovert-25 inverted microscope (Software: Axiovision 4.0).
alignedwiththenucleotidesequenceofhumanchromosome
12BACRP11-476D10(bps19612-19353)with100%homol-
ogy. The nucleotide sequence of the gene that was used for
possible protein translate indicated that the gene codes for
hypothetical protein XF2620.
Inordertoevaluatetheeﬀectsthatthe262bpsbiomarker
would have on the morphology of MCF-7 cells, the MCF-7
cellsweretransfectedwiththe262bpsbiomarker.Therewere
observable changes in the morphology of the transfected
cells. For example, the transfected cells were more elongated
and less aggregated (Figure 3).
DISCUSSION
The polymorphic biomarker with a nucleotide sequence of
262bps was present in the genomic DNA of human mam-
mary epithelial cell line MCF-10A. A single arbitrary and
short oligonucleotide primer (A25 (GCCCGTGC)) was used
in a DAF PCR reaction that produced about 50 ampliﬁca-
tion products. The selection of this primer was random be-
causethereisnorecordofanyknownDAFprimerthatworks
using human mammary epithelial cells. A detailed analy-
sis of the ampliﬁcation products showed that this polymor-
phic gene was absent from the genomic DNA of breast can-
cer cell line, MCF-7. The genomic diﬀerence between nor-
mal epithelial and breast cancer cell lines is most likely due
to the deletion of the biomarker gene from the breast can-
cer cell genome. The absence of this gene in the genome
of MCF-7cells may contribute signiﬁcantly to its carcino-
genic phenomena. The Genbank database analysis of the nu-
cleotide sequence of the polymorphic marker (Genbank ac-
count: AC079630) revealed that alignment of this gene has
100% homology with the nucleotide sequence of chromo-
some 12 BAC RP11-476D10 from bps 19612 to 19532.
Analysis of this marker by Genbank CDS indicated that
the sequence produces an alignment signiﬁcantly similar to
hypothetical protein XF2620. The XF2620 protein can be
found on the distal end of chromosome 12. Previous reports
have mentioned that the DNA architectural factor HMGA2
of chromosome 12 participates in a wide spectrum of tu-
mors. This DNA architectural factor is located in or near the
break point region of chromosome 12 [21]. The deletion of
our polymorphic biomarker from chromosome 12 of nor-
mal human epithelial cells may trigger the loss of control the
cell has over mitotic cell division, therefore generating ab-
normalities within the normal cell. We were curious as to the
eﬀects that the 262bps biomarker would have when trans-
fected into the genome of MCF-7 cells. The transfection ex-
periment resulted in increased elongation and less aggrega-
tion of the MCF-7 cells. It is most likely that the insertion
of the 262bps gene may have silenced some of the genes re-
sponsible for tumorigenesis in MCF-7 cells.
Itisourhopethatinfuturestudies,wewilltestthepoten-
tial of our DAF primer on human breast cancer solid tissue.
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